DUBLIN–(BUSINESS WIRE)–The “Digital Therapeutics: A New Age Medicine” report has been added to ResearchAndMarkets.com’s offering.
Digital therapeutics (DTx) is considered a subset of digital health. These are evidence-based, innovative interventions in which the therapeutic activity is based on algorithms and software. These interventions can be a standalone treatment or used in combination with the current medications.
Digital therapeutics are highly customizable tools and hence the growing demand for personalized and preventive treatment will be a driving factor for the market. The tool allows better involvement of the patient in the management of the disease. Thus, this technology provides an opportunity to cater to the chronic diseases segment.
Chronic diseases create a significant burden on the healthcare system in terms of morbidity and finances. Since the majority are lifestyle-related disorders, modifications in lifestyle will help to prevent or reduce the burden of the diseases. An example of this is prediabetes prevention, where DTx tools will help to prevent or delay the diagnosis of the disease. DTx also provides digital cognitive behavioral therapies (CBT), which are required for psychiatric indications such as post-traumatic stress disorder (PTSD), attention-deficit/hyperactivity disorder (ADHD), and depression. Due to the pandemic, the prevalence of these psychiatric disorders has also increased. Thus, the increasing prevalence of chronic conditions and the increasing burden of the healthcare system will lead to increased adoption of digital solutions. Compared to traditional drug development, the cost of developing digital therapeutics is relatively low.
The other factors contributing to the growth of the market include increasing investment in digital health and digital therapeutics, growing research activities, and the increasing use of smartphones, mhealth apps, and wearables. It is observed that initially only academic and tech companies were involved in the development and research of digital therapeutics. But the increasing investments in this space have attracted a number of pharma and other players in the market. The market has a number of small players and start-up companies and is expected to witness the entry of other players in the future, as many companies have ongoing pivotal trials in their portfolio.
Since this market is in its nascent stage, there is a lack of regulatory and reimbursement guidelines. Hence, developing proper regulatory and reimbursement frameworks will attract more users to the market.
- Increasing Incidence of Chronic Diseases
- Increasing Investments
- Increasing Preventive Healthcare
- Rising Use of Mhealth Apps and Wearables
- Physician Adoption
- Data Privacy and Security Concerns
- Regulatory Approval
- Growing Technology Innovations
Key Topics Covered:
Chapter 1 Market Outlook
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Chapter 4 Market Dynamics
Chapter 5 Digital Therapeutics Market by Application
Chapter 6 Digital Therapeutics Market by Sales Channel
Chapter 7 Digital Therapeutics Market by Region
Chapter 8 Competitive Landscape and Analysis of Market Opportunities
Chapter 9 Company Profiles
Chapter 10 Project Scope and Methodology
- Akili Interactive Labs Inc.
- Big Health
- Click Therapeutics
- Omada Health Inc.
- Orexo Ab
- Pear Therapeutics
- Propeller Health
For more information about this report visit https://www.researchandmarkets.com/r/j1d2oc
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900